{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:14:09Z","timestamp":1787663649620,"version":"build-2736575974"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.kisu.2021.11.005","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T05:03:32Z","timestamp":1647579812000},"page":"27-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical perspective\u2014evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2021.11.005_bib1","series-title":"IDF Diabetes Atlas","year":"2019"},{"key":"10.1016\/j.kisu.2021.11.005_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.kisu.2021.11.005_bib3","unstructured":"United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020. Accessed January 13, 2022. https:\/\/adr.usrds.org\/2020\/end-stage-renal-disease\/11-international-comparisons"},{"key":"10.1016\/j.kisu.2021.11.005_bib4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.ajkd.2018.10.005","article-title":"Trends in incidence of ESKD in people with type 1 and type 2 diabetes in Australia, 2002-2013","volume":"73","author":"Koye","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2021.11.005_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2215\/CJN.00540705","article-title":"Heart failure and nephropathy: catastrophic and interrelated complications of diabetes","volume":"1","author":"Gilbert","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2021.11.005_bib6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.kint.2017.01.030","article-title":"Diabetes with early kidney involvement may shorten life expectancy by 16 years","volume":"92","author":"Wen","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2021.11.005_bib7","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib8","doi-asserted-by":"crossref","unstructured":"Rossing P, Epstein M. Microalbuminuria constitutes a clinical action item for clinicians in 2021. Am J Med. Published online December 31, 2021. https:\/\/doi.org\/10.1016\/j.amjmed.2021.11.019","DOI":"10.1016\/j.amjmed.2021.11.019"},{"key":"10.1016\/j.kisu.2021.11.005_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib10","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib11","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2021.11.005_bib12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MNH.0000000000000557","article-title":"Mitigating risk of aldosterone in diabetic kidney disease","volume":"29","author":"Frimodt-Moller","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kisu.2021.11.005_bib14","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib15","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib16","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/ndt\/gfaa299","article-title":"Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial","volume":"36","author":"Rossing","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2021.11.005_bib17","series-title":"Brenner and Rector's The Kidney","first-page":"1283","article-title":"Diabetic nephropathy","author":"Rossing","year":"2016"},{"key":"10.1016\/j.kisu.2021.11.005_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.005_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib21","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.005_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hene","year":"1982","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2021.11.005_bib23","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1001\/archinte.1986.00360230061010","article-title":"Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction","volume":"146","author":"Reams","year":"1986","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"Sato","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kisu.2021.11.005_bib25","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.kisu.2021.11.005_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2021.11.005_bib27","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2215\/CJN.06960712","article-title":"Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy","volume":"8","author":"Moranne","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2021.11.005_bib28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2021.11.005_bib29","doi-asserted-by":"crossref","unstructured":"Nakamura T, Girerd S, Jaisser F, Barrera-Chimal J. Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease. Kidney Int Suppl. 2022;12:12\u201318.","DOI":"10.1016\/j.kisu.2021.11.004"},{"key":"10.1016\/j.kisu.2021.11.005_bib30","doi-asserted-by":"crossref","unstructured":"Luther JM, Fogo AB. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis. Kidney Int Suppl. 2022;12:63\u201368.","DOI":"10.1016\/j.kisu.2021.11.006"},{"key":"10.1016\/j.kisu.2021.11.005_bib31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1159\/000518254","article-title":"Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis","volume":"52","author":"Droebner","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2021.11.005_bib32","doi-asserted-by":"crossref","unstructured":"Hollenberg MD, Epstein M. The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets. Kidney Int Suppl. 2022;12:48\u201362.","DOI":"10.1016\/j.kisu.2021.12.001"},{"key":"10.1016\/j.kisu.2021.11.005_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.005_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.005_bib35","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2021.11.005_bib36","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2021.11.005_bib37","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"van den Meiracker","year":"2006","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.005_bib38","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2021.11.005_bib40","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.kisu.2021.11.005_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kisu.2021.11.005_bib42","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.amjms.2018.01.017","article-title":"Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy","volume":"355","author":"Chen","year":"2018","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.kisu.2021.11.005_bib43","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/dme.13669","article-title":"Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in type 2 diabetes","volume":"35","author":"Tofte","year":"2018","journal-title":"Diabet Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","article-title":"Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial","volume":"8","author":"Tofte","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.005_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study","volume":"18","author":"Lin","year":"2016","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.kisu.2021.11.005_bib46","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2021.11.005_bib47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0735-1097(02)81115-9","article-title":"Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction","volume":"39","author":"Epstein","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kisu.2021.11.005_bib48","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/S0895-7061(02)02333-6","article-title":"Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria","volume":"15","author":"Epstein","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.kisu.2021.11.005_bib49","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.005_bib50","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kisu.2021.11.005_bib51","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","article-title":"Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment","volume":"37","author":"Rossing","year":"1994","journal-title":"Diabetologia"},{"key":"10.1016\/j.kisu.2021.11.005_bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.005_bib53","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.005_bib54","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MNH.0000000000000340","article-title":"Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease","volume":"26","author":"Dojki","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kisu.2021.11.005_bib55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.005_bib56","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN)","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2021.11.005_bib57","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2021.11.005_bib58","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib59","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2021.11.005_bib60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kisu.2021.11.005_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kisu.2021.11.005_bib62","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.005_bib63","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2021.11.005_bib64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2021.11.005_bib65","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib66","doi-asserted-by":"crossref","unstructured":"Agarwal R, Anker SD, Bakris G, et\u00a0al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. Published online December 6, 2020. https:\/\/doi.org\/10.1093\/ndt\/gfaa294","DOI":"10.1093\/ndt\/gfaa294"},{"key":"10.1016\/j.kisu.2021.11.005_bib67","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kisu.2021.11.005_bib68","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2213-8587(14)70256-6","article-title":"Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis","volume":"3","author":"Wang","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.005_bib69","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCRESAHA.108.176008","article-title":"Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology","volume":"104","author":"Wilkinson-Berka","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.005_bib70","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.kint.2020.06.024","article-title":"Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2021.11.005_bib71","unstructured":"European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorisation). Kerendia (finerenone), EMA\/CHMP\/610605\/2021. Accessed January 13, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-opinion-kerendia_en.pdf"},{"key":"10.1016\/j.kisu.2021.11.005_bib72","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee; American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G, et al. 11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(suppl 1):S175\u2013S184.","DOI":"10.2337\/dc22-S011"},{"key":"10.1016\/j.kisu.2021.11.005_bib73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of\u00a0hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.kisu.2021.11.005_bib74","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc21-Sint","article-title":"Standards of medical care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kisu.2021.11.005_bib75","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.005_bib76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2021.11.005_bib77","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kisu.2021.11.005_bib78","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib79","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.005_bib80","doi-asserted-by":"crossref","first-page":"100895","DOI":"10.1016\/j.eclinm.2021.100895","article-title":"Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial","volume":"37","author":"Laursen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.kisu.2021.11.005_bib81","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.005_bib82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab."}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215717162100068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215717162100068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:51:08Z","timestamp":1775004668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215717162100068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S215717162100068X"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2021.11.005","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical perspective\u2014evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2021.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}